| Name | Title | Contact Details |
|---|
Redwood Green Corp. delivers high-quality, safe, sustainable, innovative and accessible cannabis-derived products that support individual well-being. Safety and high quality is a critical commitment from Redwood Green, both for our own brands as well as the partners with whom we do business. The drive behind what we do is rooted in improving well-being and quality of life for a wide range of audiences, ensuring we grow and improve upon what is currently available for consumers in the cannabinoids market. The company is publicly traded and listed on the OTC as RDGC.
We`re out to change the course of medical science. Are you ready to rise to the challenge? Premier Research is not about being everything to everyone. Instead, our deep, focused expertise targets the therapeutic areas and indications where today`s biotech and specialty pharma pioneers are doing the most amazing work. We`re 1,000 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers` most challenging needs. Join us and meet some of the brightest minds in clinical development today — people who apply their best thinking to every project, recognizing that what they do significantly affects the lives and well-being of customers, patients, physicians, and colleagues. You`ll enjoy great benefits and very flexible working conditions in a company that values your contributions, rewards your achievements, and is committed to helping you reach your full potential.
Mercola.com is a Hoffman Estates, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Leeway Inc is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in New Haven, CT. To find more information about Leeway Inc, please visit www.leeway.net
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.